Menu Close

Agenda

Agenda

Please check back for the most updated agenda.

June 23rdPatient Advocate Orientation

Basic tools and information for patients and advocates to make the most of the scientific sessions of the International ILC Virtual Symposium and learn about lobular breast cancer.  Everyone is welcome to attend.
12:00 – 1:30pm EST

Moderator:  Siobhán Freeney, Founding member Lobular Ireland; Patient Advocate, European Lobular Breast Cancer Consortium (ELBCC)
Karen Van Baelen, MD, KU Leuven, UZ Leuven, Leuven, Belgium: “Lobular Breast Cancer: from diagnosis to treatment
Christine Desmedt, PhD, KU Leuven, Leuven, Belgium : “The ABCs of Cancer Biology
Steffi Oesterreich, PhD, UPMC Hillman Cancer Center, Magee Womens Research Institute, University of Pittsburgh, Pittsburgh, PA: “Peculiarities of Lobular Breast Cancer Biology

June 24th – Day 1 of the International ILC Virtual Symposium Scientific Sessions

Keynote Address 

Christine Desmedt, PhD, Katholieke Universiteit, Leuven
Molecular features of lobular breast cancer: opportunities for individualizing therapy
9:00am – 10:00am EST

Presentations and Q&A: Addressing Challenges in ILC Pathology, Diagnosis and Imaging

Chair: Steffi Oesterreich, PhD, UPMC Hillman Cancer Center, Magee Womens Research Institute, University of Pittsburgh, Pittsburgh, PA
10:00am – 12:00pm EST    

10:00am
Matthias Christgen, MD, Medizinische Hochschule Hannover, Hannover, Germany
Lobular Breast Cancer: Histomorphology and different concepts of a special spectrum of tumors

10:30am
Peter Simpson, PhD, University of Queensland, Australia
Developing Lobsig – a signature capturing the molecular heterogeneity of ILC

11:00am
Jorge Reis-Filho, MD, Memorial Sloan Kettering Cancer Center, NYC
Artificial intelligence in breast pathology: beyond cancer detection

11:30am 
Hannah Linden, MD, Seattle Cancer Alliance, Seattle, WA
Imaging challenges in ILC and molecular imaging advances

Break
12:00pm – 12:30pm

Presentations and Q&A:  Addressing Challenges in ILC Treatment

Chair: Otto Metzger, MD, Dana-Farber Cancer Institute, Harvard Medical School. Boston, MA
12:30pm – 2:30pm EST

12:30pm 
Sabine Linn, MD, PhD, Netherlands Cancer Institute, Netherlands
Treatment of early-stage ILC. What is different?

1:00pm
Rinath Jeselsohn, MD, Dana Farber-Cancer Institute, Boston, MA
Estrogen signaling – what are the differences between lobular and ductal cancer?

1:30pm
Ron Bose, MD, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
Targeted anti-HER2 based therapy? Her2 mutations and treatment rationale

2:00pm
Otto Metzger, MD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Discussion with breast cancer advocates on current and future aspect of ILC tailored therapies

June 25th – Day 2 of the International ILC Virtual Symposium Scientific Sessions

Panel Discussion with Q&A: How researchers, clinicians and patient advocates can accelerate lobular breast cancer research

Leigh Pate, Founder Lobular Breast Cancer Alliance
Steffi Oesterreich, PhD, UPMC Hillman Cancer Center, Magee Womens Research Institute, University of Pittsburgh, Pittsburgh, PA
Laurie Hutcheson, Executive Director, Lobular Breast Cancer Alliance
Siobhán Freeney, Founding member Lobular Ireland; Patient Advocate, European Breast Cancer Consortium (ELBCC)
Claire Turner, Founder and Chair, Lobular Breast Cancer UK, UK Patient Advocate Representative for European Lobular Breast Cancer Consortium
9:00am – 10:00am EST

Presentations and Q&A: New Avenues in ILC Research 

Chair: Patrick Derksen, PhD, UMC Utrecht (Universitair Medisch Centrum Utrecht), The Netherland
10:00am – 12:00pm EST

10:00am
Matthew Sikora, PhDUniversity of Colorado Cancer Center, Aurora, CO
Understanding ILC as a unique context for interaction between estrogen signaling and DNA damage response

10:40am
George Sflomos, PhDSwiss Institute for Experimental Cancer Research, Lausanne, Switzerland
Novel Models of Lobular Breast Cancers: what we have learned and where we are heading

11:20am
Yeji An, University of Toronto, Toronto, Canada
Refining the ILC mouse model: exploring the role of 16q hemizygosity in breast cancer

Break
12:00pm – 12:30pm

Presentations and Q&A:  Lobular Breast Cancer Biology

Chair: Christine Desmedt, PhD, Katholieke Universiteit, Leuven
12:30pm – 2:00pm EST

12:30pm
Val Brunton, PhD, Cancer Research UK Edinburgh Centre, Edinburgh
Tumor-stromal interactions in ILC

1:00pm
Adrian Lee, PhD, UPMC Hillman Cancer, Institute for Precision Medicine, University of Pittsburgh, Pittsburgh, PA
Single-Cell transcriptomic heterogeneity in invasive ductal and lobular breast cancer cells

1:30pm
Patrick Derksen, PhD, UMC Utrecht, The Netherland
Oncogene addiction 2.0. E-cadherin loss causes vulnerabilities to targeted treatments

2:00pm
Clare Isacke, PhD, The Institute of Cancer Research, London
Characterization and modeling of lobular breast cancer leptomeningeal metastasis

June 30th – Highlights of the International ILC Virtual Symposium 

Join leading lobular breast cancer researchers and ILC advocates for a discussion of the highlights of the International ILC Virtual Symposium and Q&A.  The highlights session is open to everyone, but is tailored for patients and patient advocates.
12:00 – 1:30pm EST

Moderator:  Laurie Hutcheson, Executive Director, Lobular Breast Cancer Alliance  

Rachel C. Jankowitz, MD, Associate Professor of Clinical Medicine in the Division of Hematology/Oncology at the Perelman School of Medicine at the University of Pennsylvania, and Director of the Rena Rowan Breast Center at the Penn Abramson Cancer Center
Matthew J. Sikora, PhD, Assistant Professor of Pathology at the University of Colorado Anschutz Medical Campus
Gary A. Ulaner, MD, PhD, Chair of Molecular Imaging and Therapy at Hoag Family Cancer Institute